Thelansis

IgA Nephropathy Emerging Therapy and TPP Insights Thelansis’s “IgA Nephropathy Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication . IgA Nephropathy Overview IgA Nephropathy is the most common primary glomerulonephritis, caused by mesangial deposition of galactose-deficient IgA1 immune complexes, triggering complement activation and progressive glomerular injury. It presents with recurrent hematuria, persistent microscopic hematuria, or proteinuria. Renal biopsy with immunofluorescence confirms diagnosis; proteinuria at or above 0.5g/day, hypertension, and reduced eGFR define high progression risk. Foundational therapy combines RAS blockade, SGLT2 inhibitors, and blood pressure optimization; targeted-release budesonide and spar...

IgA Nephropathy Emerging Therapy and TPP Insights Thelansis’s “IgA Nephropathy Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication . Key business questions answered: Detailed emerging competitive landscape Pipeline analysis Target patients for emerging therapies Key companies Key mechanism of actions Launch date estimates, etc. Clinical trial landscape analysis Target patient segments Trial endpoints Trial design Recruitment criteria, etc. Unmet Needs and Opportunities Performance of key current therapies Top areas of unmet needs Opportunity sizing for key unmet needs Target Product Profiles Attributes and levels Ph...

IgA Nephropathy Market Access and Reimbursement Insights Thelansis’s “IgA Nephropathy Market Access and Reimbursement Insights Report – 2025″ provides comprehensive payer insights on the current and evolving market access and reimbursement environments for branded and emerging drugs in the indication. Our team understands the criticality of payer research and insights generation, as well as their importance during drug development, pre-market launch strategy, and post-marketing activities. Key business questions answered: Market access and reimbursement for current therapies Coverage on plans Market access restrictions Rebates and contracting Factors influencing formulary access HEOR requirements and influence, etc. Expected market access and reimbursement for key emerging therapies Level of awareness Anticipated coverage on plans Factors that would improve market access Pricin...

IgA Nephropathy Emerging Therapy and TPP Insights Thelansis’s “IgA Nephropathy Emerging Therapy, with Unmet Needs and TPP Insights Report – 2025″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication . Key business questions answered: Detailed emerging competitive landscape Pipeline analysis Target patients for emerging therapies Key companies Key mechanism of actions Launch date estimates, etc. Clinical trial landscape analysis Target patient segments Trial endpoints Trial design Recruitment criteria, etc. Unmet Needs and Opportunities Performance of key current therapies Top areas of unmet needs Opportunity sizing for key unmet needs Target Product Profiles Attributes an...

IgA Nephropathy Market Outlook Thelansis’s “IgA Nephropathy Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential IgA Nephropathy treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Key business questions answered: How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)? How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments? What is the 10-year market outlook for sales and patient share? Which events will have the greatest impact on the market’s trajectory? What insights do...

IgA Nephropathy Market Access and Reimbursement Insights Thelansis’s “IgA Nephropathy Market Access and Reimbursement Insights Report – 2025″ provides comprehensive payer insights on the current and evolving market access and reimbursement environments for branded and emerging drugs in the indication. Our team understands the criticality of payer research and insights generation, as well as their importance during drug development, pre-market launch strategy, and post-marketing activities. IgA Nephropathy Overview IgA nephropathy (IgAN) is the most prevalent form of primary glomerulonephritis worldwide. The fundamental issue of this condition lies in the abnormal glycosylation of O-linked glycans (glycoproteins) within the hinge region of IgA1 throughout the body. Consequently, there are increased galactose-deficient IgA1 (GdIgA1) levels in the bloodstream, targeted by glycan-specific IgA and IgG autoantibodies. IgA, an antibody integral to mucosal immunity, occurs in tw...

IgA Nephropathy Emerging Therapy Thelansis’s “IgA Nephropathy Emerging Therapy, with Unmet Needs and TPP Insights Report – 2024 To 2034″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication . IgA Nephropathy Overview IgA nephropathy (IgAN) is the most prevalent form of primary glomerulonephritis worldwide. The fundamental issue of this condition lies in the abnormal glycosylation of O-linked glycans (glycoproteins) within the hinge region of IgA1 throughout the body. Consequently, there are increased galactose-deficient IgA1 (GdIgA1) levels in the bloodstream, targeted by glycan-specific IgA and IgG autoantibodies. IgA, an antibody integral to mucosal immunity, occurs in two isotypes, namely IgA1 and IgA2. It can also exist as a dimeric structure known as secretory IgA. Plasma cells mainly...

IgA Nephropathy Market Outlook Thelansis’s “IgA Nephropathy Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential IgA Nephropathy treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). IgA Nephropathy Overview IgA nephropathy (IgAN) is the most prevalent form of primary glomerulonephritis worldwide. The fundamental issue of this condition lies in the abnormal glycosylation of O-linked glycans (glycoproteins) within the hinge region of IgA1 throughout the body. Consequently, there are increased galactose-deficient IgA1 (GdIgA1) levels in the bloodstream, targeted by glycan-specific IgA and IgG autoantibodies. IgA, an antibody integral to mu...

 IgA nephropathy (IgAN) is the most prevalent form of primary glomerulonephritis worldwide. The fundamental issue of this condition lies in the abnormal glycosylation of O-linked glycans (glycoproteins) within the hinge region of IgA1 throughout the body. Consequently, there are increased galactose-deficient IgA1 (GdIgA1) levels in the bloodstream, targeted by glycan-specific IgA and IgG autoantibodies. IgA, an antibody integral to mucosal immunity, occurs in two isotypes, namely IgA1 and IgA2. It can also exist as a dimeric structure known as secretory IgA. Plasma cells mainly produce secretory IgA in a polymeric form, consisting of multiple monomers linked by the J-chain, a 17-kDa polypeptide. In IgAN, the kidneys sustain the primary damage. The disease follows a gradual yet relentless clinical course, leading to end-stage renal disease (ESRD) in approximately 30-40% of patients within 20-30 years. IgAN can manifest in sporadic cases (90-95%) or familial cases (5-10%). Individual...

  IgA nephropathy (IgAN) is the most common type of primary glomerulonephritis in the world. The primary defect of the disease is systemic aberrant glycosylation of O­linked glycans (glycoproteins) in the hinge region of IgA1, resulting in elevated serum levels of galactose-deficient IgA1 (GdIgA1), which is recognised by glycan-specific IgA and IgG autoantibodies. IgA is an antibody that plays an important part in mucosal immunity. Prevalence is modest in the United States (10–20% of primary glomerulonephritis), higher in some European countries (20–30%), and highest in developed countries in Asia (40–50%). Thelansis’s “IgA Nephropathy Market Outlook, Epidemiology, Competitive Landscape , and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potenti...